# Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

> **NCT03870399** · PHASE2 · COMPLETED · sponsor: **AC Camargo Cancer Center** · enrollment: 23 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Progesterone Receptor Positive Tumor
- Estrogen Receptor Positive Tumor

## Interventions

- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT03870399
- **Lead sponsor:** AC Camargo Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-13
- **Primary completion:** 2023-05-13
- **Final completion:** 2023-05-13
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2024-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03870399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03870399, "Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03870399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*